Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free EVLO Stock Alerts

Evelo Biosciences (EVLO) Competitors

Evelo Biosciences logo
Compare

EVLO vs. CARM, GNCA, SMFL, GNCAQ, and SYRS

Should you buy Evelo Biosciences stock or one of its competitors? MarketBeat compares Evelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evelo Biosciences include Carisma Therapeutics (CARM), Genocea Biosciences (GNCA), Smart for Life (SMFL), Genocea Biosciences (GNCAQ), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry.

How does Evelo Biosciences compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Evelo Biosciences Neutral

Carisma Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Evelo Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Evelo Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Carisma Therapeutics has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Evelo Biosciences has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Evelo Biosciences N/A N/A N/A

Summary

Carisma Therapeutics beats Evelo Biosciences on 10 of the 13 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Evelo Biosciences Neutral

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market.

Genocea Biosciences has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Evelo Biosciences N/A N/A N/A

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Genocea Biosciences beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.

How does Evelo Biosciences compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Smart for Life has a beta of 13.95, suggesting that its stock price is 1,295% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Evelo Biosciences Neutral

Smart for Life has higher revenue and earnings than Evelo Biosciences. Smart for Life is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Summary

Smart for Life beats Evelo Biosciences on 5 of the 7 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Evelo Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Evelo Biosciences Neutral

0.3% of Evelo Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Genocea Biosciences has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market.

Summary

Genocea Biosciences and Evelo Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does Evelo Biosciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Evelo Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Evelo Biosciences N/A N/A N/A

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Evelo Biosciences Neutral

Evelo Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Summary

Evelo Biosciences beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVLO vs. The Competition

Export
MetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio0.001.4621.0025.66
Price / SalesN/A119.63562.1886.31
Price / CashN/A20.0743.4956.67
Price / BookN/A7.5910.417.14
Net Income-$114.53M-$3.64M$3.57B$335.98M

Evelo Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120
CARM
Carisma Therapeutics
2.3139 of 5 stars		$0.00
+100.0%		$1.00
+499,900.0%		-99.9%$8K$10.77M0.0020
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
SMFL
Smart for Life
N/A$0.00
+33.3%		N/A-64.0%$6K$11.11MN/A110
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel